Ectodysplasin A2 Receptor anticorps

N° du produit ABIN6990649

Détail du produit anti-Ectodysplasin A2 Receptor anticorps

Antigène: Ectodysplasin A2 Receptor (EDA2R)

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp Ectodysplasin A2 Receptor est non-conjugé

Application: Western Blotting (WB), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Purification: XEDAR Antibody is affinity chromatography purified via peptide column.

Immunogène: XEDAR antibody was raised against recombinant human XEDAR.

Isotype: IgG

Information d'application

Indications d'application: XEDAR antibody can be used for the detection of XEDAR by Western blot at 0.5 - 2 μ,g/mL. Antibody can also be used for immunohistochemistry starting at 10 μ,g/mL.

Antibody validated: Western Blot in human samples and Immunohistochemistry in human samples. All other applications and species not yet tested.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: XEDAR Antibody is supplied in PBS containing 0.02 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C,4 °C

Stockage commentaire: XEDAR antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Détails sur Ectodysplasin A2 Receptor

Antigène: Ectodysplasin A2 Receptor (EDA2R)

Autre désignation: XEDAR (EDA2R Produits)

Synonymes: anticorps EDA-A2R, anticorps EDAA2R, anticorps TNFRSF27, anticorps XEDAR, anticorps 9430060M22Rik, anticorps Xedar, anticorps RGD1564025, anticorps ectodysplasin A2 receptor, anticorps EDA2R, anticorps Eda2r

Sujet: XEDAR Antibody: X-linked ectodysplasin-A2 receptor (XEDAR) is a recently isolated member of the tumor necrosis factor receptor family that is highly expressed during embryonic development and binds to ectodysplatin-A2 (EDA-A2). Two predominantly expressed isoforms, XEDAR-s and XEDAR-L, differ by only a 21-amino region at the juxtamembrane region of the cytoplasmic domain. Neither isoform possesses a death domain and both have been shown to act mainly through TRAF3 and TRAF6 to activate the NF-κ,B and JNK pathways. Cells transfected with XEDAR and treated with EDA-A2 cause the assembly of a secondary complex containing FADD, caspase-8 and caspase-10, leading to the activation caspase-8 and caspase-3, and finally apoptosis. The EDA-A2-induced apoptosis is dependent on caspase-9 activation, as various pharmacological and genetic inhibitors of caspase-8 blocked apoptosis following EDA-A2 treatment.

ID gène: 60401

UniProt: Q9HAV5